Higher risk of liver cancer seen in women with intrahepatic cholestasis of pregnancy
the ONA take:
Researchers at the Sahlgrenska Academy found that women with intrahepatic cholestasis of pregnancy (ICP) are at increased risk of hepatobiliary cancer and immune-mediated and cardiovascular diseases later in life.
Using the Swedish Medical Birth Register and the Swedish Patient Register, the investigators identified 11,388 women with ICP and 113,893 women without ICP who gave birth between 1973 and 2009.
Study findings showed risk for cancer in the biliary tree and risk for liver cancer were 2.5 times higher and 3.5 times higher, respectively, compared with matched controls. In addition, patients with ICP were found to be at higher risk for thyroid disease, diabetes, psoriasis, and Crohn’s disease. Women with both ICP and preeclampsia during pregnancy had a slightly higher risk for cardiovascular disease.
The investigators recommend follow-up of serum liver tests 6 to 12 weeks after delivery for all women with ICP, and further evaluation by a hepatologist if serum liver tests results are elevated.
Women with intrahepatic cholestasis of pregnancy (ICP) are at increased risk of hepatobiliary cancer.
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|